Planning Your Regulatory Pathway Around Your Product Roadmap: Interview with Virtual Incision CEO John Murphy Recently, Virtual Incision CEO John Murphy was featured on the Medsider Podcast with Scott Nelson. In this episode of Medsider, John outlines his best advice on fundraising, regulatory approvals, and the dual-track approach to exiting. Listen to John's interview
FDA decision supported by an interim clinical study report on patient safety Lincoln, Neb. – April 19, 2022 – Virtual Incision Corporation, a medical device company pioneering the world’s first miniaturized robotic-assisted surgery (RAS) platform, today announced the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) supplement to complete the final stage […]
IDE clinical study of robotic-assisted MIRA Surgical Platform currently underway for laparoscopic colon surgery
Medgadget had the opportunity to talk to John Murphy, CEO of Virtual Incision about the MIRA.
Download Press Release Virtual Incision Corporation, a medical device company pioneering a first-of-its-kind miniaturized surgical platform, today announced it has received an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) for the company’s MIRA (“miniaturized in vivo robotic assistant”) Platform. The IDE will allow the company to initiate a clinical study of MIRA […]
Today, Virtual Incision Corporation, a medical device company pioneering a first-of-its-kind miniaturized surgical robot, announced it has raised $20 million in a Series B+ financing led by returning investor Bluestem Capital, with participation from returning investor PrairieGold Venture Partners, as well as from Genesis Innovation Group and other affiliated investors. The funds will support regulatory […]